Table 1:

List of emerging clinical trials for the prevention and treatment of CIPN

Intervention	Target/Pathway	N	Patient Population (NCT # if available)	References
Nilotinib	OATP1B1-3 uptake transporter inhibitor	95	Breast cancer patients initiating paclitaxel	(25,71)
Dasatinib	OCT2 uptake transporter inhibitor	20	Stage 4 colorectal patients initiating oxaliplatin-based therapy	(22,72)
Calmangafodipir	Reduction of ROS	1) 420 2) 280	1) Stage 4 colorectal patients initiating oxaliplatin-based therapy (POLAR M ) 2) Adjuvant oxaliplatin based therapy (POLAR A)	(31,73)
APX3330	Enhance APE1 expression	30	Adjuvant oxaliplatin-based therapy	(39,40)
Fingolimod	S1PR1 antagonism	1)10-20 2)10-20	1)breast cancer patients initiating adjuvant paclitaxel 2) patients with established long-standing CIPN	(43,44)
Duloxetine	Serotonin-norepinephrine reuptake inhibitor	248	Patients initiating oxaliplatin-based adjuvant therapy	(20,74)
GM-1	Lipid peroxidation inhibition	188	Patients initiating oxaliplatin-based adjuvant therapy ()	(53,75)